2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Wade T. Iams, MD, discusses the key implications of the phase 3 ADAURA trial in non–small cell lung cancer.
Wade T. Iams, MD, assistant professor of medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, discusses the key implications of the phase 3 ADAURA trial (NCT02511106) in non–small cell lung cancer (NSCLC).
The ADAURA trial demonstrated the importance of EGFR genotyping in patients with resected NSCLC, Iams says. This mutation analysis allows practitioners to determine whether these patients have an EGFR exon 21 L858R mutation or exon 19 deletion, Iams explains.
Data from the trial’s primary end point of disease-free survival (DFS) led to the December 2020 FDA approval of osimertinib (Tagrisso) as an adjuvant treatment following tumor resection in patients with NSCLC whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations, Iams continues. Osimertinib elicited a significant prolongation of DFS, but more research is needed to determine if adjuvant treatment will improve overall survival, Iams concludes.